APIXABAN VIATRIS 5 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Apixaban Viatris 5mg film-coated tablets EFG

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What is Apixaban Viatris and what is it used for
2. What you need to know before you take Apixaban Viatris
3. How to take Apixaban Viatris
4. Possible side effects
5. Storing Apixaban Viatris
6. Contents of the pack and other information

1. What is Apixaban Viatris and what is it used for

Apixaban Viatris contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent the formation of blood clots by blocking factor Xa, an important component of blood clotting.

Apixaban is used in adults:

• To prevent the formation of a blood clot in the heart in patients with an irregular heartbeat (atrial fibrillation) and at least one additional risk factor. Blood clots can break loose, travel to the brain, and cause a stroke, or travel to other organs and prevent proper irrigation (also known as systemic embolism). A stroke can be life-threatening and requires immediate medical attention.
• To treat blood clots in the veins of the legs (deep vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), and to prevent these blood clots from recurring in the blood vessels of the legs and/or lungs.

2. What you need to know before you take Apixaban Viatris

Do not take Apixaban Viatris

• to apixaban or any of the other ingredients of this medicine (listed in section 6)
• that increases the risk of severe bleeding (such as an active or recent stomach or intestinal ulcer, or recent brain hemorrhage)
• that increases the risk of bleeding (hepatic coagulopathy)
• (e.g., warfarin, rivaroxaban, dabigatran, or heparin), except when switching from one anticoagulant treatment to another, while having an arterial or venous line and being treated with heparin to keep the line open, or when having a tube inserted into a blood vessel (catheter ablation) to treat an irregular heartbeat (arrhythmia).

Warnings and precautions

Tell your doctor, pharmacist, or nurse before taking this medicine if you have any of the following conditions:

• an increased risk of bleeding, such as:

• bleeding disorders, including diseases that result in decreased platelet activity
• very high blood pressurethat is not controlled by medical treatment
• you are over 75 years old
• you weigh 60 kg or less

• severe kidney disease or if you are on dialysis
• a liver problem or history of liver problems

This medicine will be used with caution in patients with signs of altered liver function

• you have a heart valve replacement
• if your doctor determines that your blood pressure is unstable or you are scheduled to receive another treatment or undergo surgery to remove the blood clot from your lungs

Be careful with apixaban

• if you know you have a disease called antiphospholipid syndrome(an immune system disorder that increases the risk of blood clots), inform your doctor to decide if it may be necessary to modify the treatment.

If you need to have surgery or a procedure that may cause bleeding, your doctor will tell you to temporarily stop taking this medicine for a short time. If you are unsure whether a procedure may cause bleeding, consult your doctor.

Children and adolescents

This medicine is not recommended for use in children and adolescents under 18 years of age.

Other medicines and Apixaban Viatris

Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.

Some medicines may increase the effects of apixaban and others may decrease its effects. Your doctor will decide if you should be treated with apixaban if you are taking these medicines and if you should be kept under closer observation.

The following medicines may increase the effects of apixaban and increase the risk of unwanted bleeding:

• some medicines for fungal infections(e.g., ketoconazole, etc.)
• some antiviral medicines for HIV/AIDS(e.g., ritonavir)
• other medicines to reduce blood clotting(e.g., enoxaparin, etc.)
• anti-inflammatory medicinesor medicines to relieve pain(e.g., acetylsalicylic acid or naproxen). In particular, if you are over 75 years old and taking acetylsalicylic acid, there is a higher likelihood of bleeding
• medicines for high blood pressure or heart problems(e.g., diltiazem)
• antidepressantscalled selective serotonin reuptake inhibitorsor serotonin and norepinephrine reuptake inhibitors

The following medicines may reduce the ability of apixaban to prevent blood clots:

• medicines for the treatment of epilepsy or seizures(e.g., phenytoin, etc.)
• St. John's Wort(a herbal medicine for the treatment of depression)
• medicines to treat tuberculosisor other infections(e.g., rifampicin)

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor, pharmacist, or nurse for advice before taking this medicine.

The effects of Apixaban Viatris on pregnancy and the fetus are not known. You should not take this medicine if you are pregnant. Tell your doctor immediatelyif you become pregnant while taking this medicine.

It is not known whether apixaban is excreted in breast milk. Ask your doctor, pharmacist, or nurse before taking this medicine during breastfeeding. They will tell you whether to stop breastfeeding or to stop or not start taking this medicine.

Driving and using machines

Apixaban has not been shown to affect the ability to drive or use machines.

Apixaban Viatris contains lactose (a type of sugar) and sodium

If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.

This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".

3. How to take Apixaban Viatris

Always take this medicine exactly as your doctor or pharmacist has told you. If you are unsure, check with your doctor, pharmacist, or nurse.

Dosage

Take the tablet with water. Apixaban Viatris can be taken with or without food. Try to take the tablets at the same time each day to achieve a better treatment effect.

If you have difficulty swallowing the tablet whole, talk to your doctor about other possible ways to take apixaban. The tablet can be crushed and mixed with water, 5% glucose in water, apple juice, or apple puree, immediately before taking it.

Instructions for crushing:

• Crush the tablets with a mortar.
• Transfer all the powder carefully into a suitable container, mixing the powder with a small amount, for example, 30 ml (2 tablespoons), of water or any of the other liquids mentioned above to make the mixture.
• Take the mixture.
• Rinse the mortar and pestle used to crush the tablet and the container with a small amount of water or one of the other liquids (e.g., 30 ml), and take that liquid.

If necessary, your doctor may also administer the crushed apixaban tablet mixed in 60 ml of water or 5% glucose in water through a nasogastric tube.

Take Apixaban Viatris according to the following recommendations:

To prevent the formation of a blood clot in the heart in patients with an irregular heartbeat and at least one additional risk factor.

The recommended dose is one apixaban 5mgtablet twice a day.

The recommended dose is one apixaban 2.5mgtablet twice a day if:

• you have severely decreased kidney function
• you have two or more of the following factors:

• your blood test results suggest poor kidney function(serum creatinine value of 1.5 mg/dl [133 micromoles/l] or higher)
• you are 80 years old or older
• your weight is 60 kg or less

The recommended dose is one tablet twice a day, for example, take one tablet in the morning and one in the evening. Your doctor will tell you how long to continue the treatment.

To treat blood clots in the veins of the legs and in the blood vessels of the lungs

The recommended dose is twoapixaban 5mgtablets twice a day for the first 7 days, for example, two tablets in the morning and two tablets in the evening.

After 7 days, the recommended dose is oneapixaban 5mgtablet twice a day, for example, one tablet in the morning and one in the evening.

To prevent blood clots from recurring after 6 months of treatment

The recommended dose is one apixaban 2.5mgtablet twice a day, for example, one tablet in the morning and one in the evening.

Your doctor will tell you how long to continue the treatment.

Your doctor may change your anticoagulant treatment as follows:

• Switching from Apixaban Viatris to other anticoagulant medicines

Stop taking Apixaban Viatris. Start treatment with other anticoagulant medicines (e.g., heparin) at the time you would take the next tablet.

• Switching from other anticoagulant medicines to Apixaban Viatris

Stop taking other anticoagulant medicines. Start treatment with Apixaban Viatris at the time you would take the next dose of an anticoagulant medicine, and then continue as usual.

• Switching from a treatment with anticoagulants that contain vitamin K antagonists (e.g., warfarin) to Apixaban Viatris

Stop taking the medicine that contains a vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to start taking Apixaban Viatris.

• Switching from Apixaban Viatris to a treatment with anticoagulants that contain vitamin K antagonists (e.g., warfarin).

If your doctor tells you to start taking a medicine that contains a vitamin K antagonist, continue taking Apixaban Viatris for at least 2 days after your first dose of the medicine that contains a vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to stop taking Apixaban.

Patients undergoing cardioversion

If your irregular heartbeat needs to be restored through a procedure called cardioversion, take this medicine at the times your doctor tells you to prevent blood clots in the blood vessels of the brain and other blood vessels in the body.

If you take more Apixaban Viatris than you should

Tell your doctor immediatelyif you have taken a dose higher than the prescribed dose of this medicine. Take the package of the medicine to your doctor, even if there are no tablets left.

If you take more apixaban than the recommended dose, you may increase the risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that can reverse anti-factor Xa activity may be necessary.

In case of overdose or accidental ingestion, consult your doctor or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Apixaban Viatris

Do not take a double dose to make up for forgotten tablets.

Take the dose as soon as you remember and:

• take the next dose of apixaban at the usual time
• then continue taking the medicine as usual

If you have doubts about what to do or if you forget to take more than one dose,ask your doctor, pharmacist, or nurse.

If you stop taking Apixaban Viatris

Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot may be higher if you stop treatment too soon.

If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. The most frequent adverse effect of this medicine is bleeding, which can put the patient's life at risk and requires immediate medical attention.

The following adverse effects have been reported when taking Apixabán Viatris to prevent the formation of blood clots in the heart in patients with irregular heart rhythm and at least one additional risk factor.

Frequent Adverse Effects (may affect up to 1 in 10 people)

• Bleeding, including:

• in the eyes
• in the stomach or intestine
• from the rectum
• blood in the urine
• from the nose
• from the gums
• hematoma and swelling

• Anemia, which can cause fatigue or paleness
• Low blood pressure that can cause fainting or a faster heart rate
• Nausea (general discomfort)
• Blood tests may show:

• an increase in gamma glutamyl transferase (GGT)

Infrequent Adverse Effects (may affect up to 1 in 100 people)

• Bleeding:

• in the brain or spinal cord
• in the mouth and coughing up blood
• in the abdomen or vagina
• bright red blood in the stool
• bleeding after surgery, including hematoma and swelling, blood or fluid secretion from the wound/surgical incision (suppuration), or at the injection site
• hemorrhoidal
• tests showing blood in the stool or urine

• Decrease in the number of platelets in the blood (which can affect coagulation)
• Blood tests may show:

• abnormal liver function
• increase in some liver enzymes
• increase in bilirubin, a byproduct of red blood cells, which can cause yellowing of the skin and eyes

• Skin rash
• Itching
• Hair loss
• Allergic reactions (hypersensitivity) that can cause: swelling of the face, lips, mouth, tongue, and/or throat, and difficulty breathing. Inform your doctor immediatelyif you experience any of these symptoms.

Rare Adverse Effects (may affect up to 1 in 1,000 people)

• Bleeding:

• in the lungs or throat
• in the space behind the abdominal cavity
• in a muscle

Very Rare Adverse Effects (may affect up to 1 in 10,000 people)

• Skin rash that can form blisters and resemble small targets (dark spots in the center surrounded by a paler area, with a dark ring around) (erythema multiforme).

Unknown Frequency (cannot be estimated from available data)

• Inflammation of blood vessels (vasculitis) that can cause skin rash, appearance of red round and smooth spots under the skin surface, or hematomas.

The following adverse effects have been reported when taking Apixabán Viatris to treat or prevent blood clots from recurring in the veins of the legs and in the blood vessels of the lungs.

Frequent Adverse Effects (may affect up to 1 in 10 people)

• Bleeding, including:

• from the nose
• from the gums
• blood in the urine
• hematoma and swelling
• from the stomach, intestine, or rectum
• in the mouth
• vaginal

• Anemia, which can cause fatigue or paleness
• Decrease in the number of platelets in the blood (which can affect coagulation)
• Nausea (general discomfort)
• Skin rash
• Blood tests may show:

• an increase in gamma glutamyl transferase (GGT) or alanine aminotransferase (GPT)

Infrequent Adverse Effects (may affect up to 1 in 100 people)

• Low blood pressure that can cause fainting or a faster heart rate
• Bleeding:

• in the eyes
• in the mouth and coughing up blood
• bright red blood in the stool
• tests showing blood in the stool or urine
• bleeding after surgery, including hematoma and swelling, blood or fluid secretion from the wound/surgical incision (suppuration), or at the injection site
• hemorrhoidal
• in a muscle

• Itching
• Hair loss
• Allergic reactions (hypersensitivity) that can cause: swelling of the face, lips, mouth, tongue, and/or throat, and difficulty breathing. Inform your doctor immediatelyif you experience any of these symptoms.
• Blood tests may show:

• abnormal liver function
• increase in some liver enzymes
• increase in bilirubin, a byproduct of red blood cells, which can cause yellowing of the skin and eyes

Rare Adverse Effects (may affect up to 1 in 1,000 people)

• Bleeding:

• in the brain or spinal cord
• in the lungs

Unknown Frequency (cannot be estimated from available data)

• Bleeding:

in the abdomen or the space behind the abdominal cavity

• Skin rash that can form blisters and resemble small targets (dark spots in the center surrounded by a paler area, with a dark ring around) (erythema multiforme).
• Inflammation of blood vessels (vasculitis) that can cause skin rash, appearance of red round and smooth spots under the skin surface, or hematomas.

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is an adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of Apixabán Viatris

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date that appears on the packaging and on each blister, after "CAD/EXP". The expiration date is the last day of the month indicated.

This medicine does not require special storage conditions.

Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.

6. Package Contents and Additional Information

Contents of Apixabán Viatris

• The active ingredient is apixaban. Each tablet contains 5 mg of apixaban.
• The other components are:
• • Core of the tablet: , microcrystalline cellulose (E-460), croscarmellose sodium, laurilsulfate sodium, magnesium stearate (E-470b).
  • Coating: , hypromellose (E-464), titanium dioxide (E-171), triacetin, iron oxide red (E-172).

Appearance of the Product and Package Contents

The film-coated tablets are pink, oval (approximately 5.2 x 9.8 mm wide), biconvex (curved surfaces on both sides), and are marked with "IU2" on one side and smooth on the other.

Apixabán Viatris is available in:

• blister packs in boxes containing 14, 20, 28, 56, 60, 100, 168, and 200 tablets, or
• single-dose blister packs in boxes of 14x1, 20x1, 28x1, 56x1, 60x1, 100x1, 168x1, or 200x1 tablets, or
• bottles with 60, 120, 180, or 1,000 tablets. The bottles of 60 film-coated tablets have a child-resistant screw cap.

Not all pack sizes may be marketed.

Patient Information Card: Information Management

This prospectus contains a Patient Information Card. This Patient Information Card includes useful information for you and will inform other doctors that you are being treated with Apixabán Viatris. You must keep this card with you at all times.

Cut out the card from the prospectus and complete the following sections or ask your doctor to complete them:

• Name:
• Date of birth:
• Indication:
• Dose: …….. mg twice a day
• Doctor's name:
• Doctor's phone number:

Carry this card with you at all times.

Marketing Authorization Holder

Viatris Pharmaceuticals, S.L.U.

C/ General Aranaz, 86

28027 - Madrid

Spain

Manufacturers

McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin, Unit 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland.

Or

Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Hoehe, Benzstrasse 1, Bad Homburg v. d. Hoehe, Hessen, 61352, Germany.

Or

Mylan Hungary Kft.

2900 Komárom

Mylan utca 1

Hungary

This medicine has been authorized in the EEA member states with the following names:

Germany Apixaban Mylan 5 mg film-coated tablets

Austria Apixaban Mylan 5 mg film-coated tablets

Belgium Apixaban Mylan 5 mg film-coated tablets

Bulgaria Apixaban Mylan 5 mg film-coated tablets

Cyprus Apixaban / Mylan 5 mg film-coated tablets

Denmark Apixaban Mylan

Spain Apixabán Viatris 5 mg film-coated tablets EFG

Estonia Apixaban Mylan

Finland Apixaban Mylan

France Apixaban Viatris 5 mg film-coated tablets

Greece Apixaban / Mylan 5 mg film-coated tablets

Hungary Apixaban 5 mg film-coated tablets

Ireland Apixaban Mylan 5 mg film-coated tablets

Iceland Apixaban Mylan

Italy Apixaban Mylan

Latvia Apixaban Mylan 5 mg film-coated tablets

Lithuania Apixaban Mylan 5 mg film-coated tablets

Luxembourg Apixaban Mylan 5 mg film-coated tablets

Malta Apixaban Mylan 5 mg film-coated tablets

Norway Apixaban Mylan

Netherlands Apixaban Mylan 5 mg film-coated tablets

Portugal Apixabano Mylan

Czech Republic Apixaban Mylan

Slovakia Apixaban Mylan 5 mg

Sweden Apixaban Mylan

United Kingdom (Northern Ireland) Apixaban Mylan 5 mg film-coated tablets

Date of the last revision of this prospectus:April 2022.

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/